Canon Inc. vs Cardinal Health, Inc.: Strategic Comparison

This in-depth comparison examines Canon Inc. and Cardinal Health, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Canon Inc. on its own, evaluating Cardinal Health, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Canon Inc. and Cardinal Health, Inc. is widest.

On the headline numbers, Canon Inc. reports annual revenue of ~$31B against $254.2B for Cardinal Health, Inc., while their respective market capitalizations stand at $25.6B and $56.0B. Canon Inc. is headquartered in Japan and Cardinal Health, Inc. in United States, and those different home markets shape how each company competes.

Canon Inc.: Canon is a diversified Japanese manufacturer organized into four business units. Printing (office multifunction devices, laser and inkjet printers, production presses) is the largest. Imaging includes EOS cameras, RF lenses, cinema cameras and Axis network cameras. Medical, built on the 2016 purchase of Toshiba Medical Systems, makes CT, MRI, ultrasound and X-ray equipment. Industrial supplies semiconductor and flat-panel lithography tools and Canon Tokki OLED deposition systems. The group had 321 consolidated subsidiaries and 165,547 employees at the end of 2025, and its shares trade on the Tokyo Stock Exchange under code 7751.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Canon Inc. and Cardinal Health, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Canon Inc. and Cardinal Health, Inc..

Canon Inc. business model: Canon designs, builds and sells hardware, then earns recurring revenue from consumables, service contracts and software on the installed base. In 2025 the Printing Business Unit produced ~$16.7 billion (¥2,494.4 billion) of sales (54%), split between office multifunction devices (~$7.13 billion (¥1,063.7 billion)), prosumer laser and inkjet printers (~$6.66 billion (¥993.4 billion)) and production presses (~$2.93 billion (¥437.3 billion)); toner, ink and maintenance on machines already in the field account for much of that income. Imaging (~$7.07 billion (¥1,054.9 billion), 23%) covers EOS cameras and lenses (~$4.19 billion (¥625.5 billion)) plus network cameras and video software from Axis and Milestone (~$2.88 billion (¥429.4 billion)). Medical (~$3.89 billion (¥580.6 billion), 13%) sells CT, MRI, ultrasound and X-ray systems and service. Industrial (~$2.42 billion (¥361.1 billion), 8%) sells semiconductor and flat-panel lithography tools, Canon Tokki OLED deposition systems and sputtering equipment. Canon sells through regional companies such as Canon U.S.A., Canon Europe and Canon Marketing Japan, and spent ~$2.27 billion (¥339.3 billion), about 7.3% of sales, on R&D in 2025.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Canon Inc. stack up against those of Cardinal Health, Inc..

Canon Inc. competitive advantage: Canon's edge is vertical integration in optics and imaging. It designs its own lenses, CMOS image sensors, print engines and image-processing chips, and builds much of its own production equipment. That depth shows in its patent output (seventh in U.S. patent grants in 2025 and in the top 10 for 42 straight years, according to IFI Claims) and in a camera business that has held the No. 1 interchangeable-lens share for 23 consecutive years. In printing, a large installed base of office devices produces recurring toner and service revenue that new entrants cannot easily copy.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Future prospects matter as much as current results. The growth strategies below explain how Canon Inc. and Cardinal Health, Inc. each plan to expand from here.

Canon Inc. growth strategy: Phase VII sets 2030 sales targets for each unit: Printing ~$18.8 billion (¥2.8 trillion) (about 2% a year), Imaging ~$8.98 billion (¥1.34 trillion) (5%), Medical ~$5.03 billion (¥750 billion) (5%) and Industrial ~$4.02 billion (¥600 billion) (10%). Growth products named in the plan are nanoimprint lithography, photon-counting CT and industrial printing equipment. Canon merged Canon Medical Systems' operations into Canon Inc. on April 1, 2026, is taking Canon Electronics private to build a space business worth ~$134 million (¥20 billion) or more in sales by 2030, and wants emerging markets such as India, Indonesia, Africa, the Middle East and Latin America to rise from 10% to 15% of sales. In Printing it plans to cut production staff by 30% and factory space by 40% by 2028 and to outsource hardware that needs no special technology.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

A closer look at the financial trajectory of Canon Inc. and Cardinal Health, Inc. rounds out the comparison.

Canon Inc.: Canon's sales fell from ~$27.3 billion (¥4,080.0 billion) in 2017, the first full year with Toshiba Medical, to ~$21.2 billion (¥3,160.2 billion) in 2020 as cameras and office printing shrank and the pandemic hit. They have grown every year since, reaching a record ~$31 billion (¥4,624.7 billion) in 2025 (+2.5%). Operating profit was ~$3.05 billion (¥455.4 billion) in 2025, a 9.8% margin, up from ~$1.87 billion (¥279.8 billion) in 2024, when a ~$1.11 billion (¥165.1 billion) goodwill impairment on the medical business cut net income to ~$1.07 billion (¥160.0 billion). Net income attributable to Canon Inc. more than doubled to ~$2.23 billion (¥332.1 billion) and EPS rose to ¥367.48. Canon paid a ¥160 dividend (42.9% payout), generated ~$1.6 billion (¥238.5 billion) of free cash flow and ended 2025 with ~$6.34 billion (¥946.2 billion) of interest-bearing debt, up from ~$4.45 billion (¥663.5 billion). By region, the Americas supplied 32% of 2025 sales, Europe 26%, Japan 21% and Asia and Oceania 21%. In July 2026, after record second-quarter sales, Canon guided to ~$32.2 billion (¥4,800.0 billion) of 2026 sales and ~$3.12 billion (¥465.0 billion) of operating profit.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.